<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546139/" ref="ordinalpos=480&amp;ncbi_uid=5661749&amp;link_uid=PMC3546139" image-link="/pmc/articles/PMC3546139/figure/F4/" class="imagepopup">Figure 4. Selenocoxib-1-GSH inhibited Akt <span class="highlight" style="background-color:">signaling</span> to reduce the proliferative potential and promote apoptotic <span class="highlight" style="background-color:">signaling</span> in melanoma cells.  From: Simultaneous Targeting of COX-2 and AKT Using Selenocoxib-1-GSH to Inhibit Melanoma. </a></div><br /><div class="p4l_captionBody">4A. Selenocoxib-1-GSH inhibits the PI3K/Akt signaling pathway. 4B. Selenocoxib-1-GSH activates the MAPK signaling pathway. 4C. Selenocoxib-1-GSH decreased cyclin D1 protein levels indicating a reduction in cellular proliferation. 4D. Selenocoxib-1-GSH increased levels of cellular apoptosis.</div></div>